Indication Selection


A Life sciences venture capital firm come to Halloran looking for help prioritizing potential indications for their lead oncology compound.


  • Halloran drew from experience, guidelines, and precedence to determine the optimal development strategy and clinical and regulatory considerations, including ballpark costs and timeframes, for 8 potential indications.
  • Halloran outlined risks and potential roadblocks for each of the selected indications, ranked by severity
  • Halloran provided  a clear-cut and effective methodology for scoring the potential 8 indications


The client was able to confidently prioritize development of indication and progress swiftly to go/no-go indication decisions. Halloran’s expertise was able to guide leadership to the most efficient pathway to market.